New Herceptin biosimilar under EMA review

29 May 2019
ema-big-1

Following in the footsteps of Celltrion (Kosdaq: 068270), Samsung Bioepis, Amgen (Nasdaq: AMGN) and others, Prestige BioPharma is making headway with its Herceptin (trastuzumab) biosimilar.

The Singapore-based company has had its marketing authorization application (MAA) approved by the European Medicines Agency (EMA), giving it the chance of reaching a major market with a copy of the Roche (ROG: SIX) drug, which is indicated for HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Prestige’s Phase I/III data on its HD201 candidate includes results showing exceptional biosimilarity to Herceptin in terms of clinical response and pharmacokinetics, and a comparable safety profile to the range previously observed in Herceptin biosimilar trials.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars